公开(公告)号：US20240335468A1

公开(公告)日：2024-10-10

申请号：US18578811

申请日：2022-07-08

Applicant: HYPO-STREAM LIMITED

Inventor： Myles Dakin ,  Richard Aspinall ,  Thomas Kenny

IPC: A61K33/20 ,  A61K9/00 ,  A61K9/08 ,  A61K47/02 ,  A61P1/18 ,  A61P11/00 ,  A61P19/02 ,  A61P31/14 ,  A61P37/02

CPC classification number: A61K33/20 ,  A61K9/0078 ,  A61K9/008 ,  A61K9/08 ,  A61K47/02 ,  A61P1/18 ,  A61P11/00 ,  A61P19/02 ,  A61P31/14 ,  A61P37/02

Abstract: The present invention relates to a hypochlorite solution for use in the prevention or treatment of a respiratory condition or disease in a patient; preferably a mammal, more preferably a human. The present invention also relates to a hypochlorite solution for use in the prevention or treatment of an inflammatory or auto-immune response, condition or disease in a patient, preferably a mammal, more preferably a human, wherein administration of the hypochlorite solution is by inhalation of the hypochlorite solution. The hypochlorite solution comprises hypochlorite in a concentration range of about 0.005-0.2 wt % (about 50-2000 ppm by wt).

公开(公告)号：US20240228585A1

公开(公告)日：2024-07-11

申请号：US18558640

申请日：2022-05-02

Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： Jeffrey Charles WAY ,  Katherine REDFIELD CHAN ,  Jungmin LEE ,  Florian BIEBERICH ,  Daniel HEID ,  Dominik NIOPEK

IPC: C07K14/715 ,  A61K38/00 ,  A61P1/18 ,  C07K14/47

CPC classification number: C07K14/7155 ,  A61P1/18 ,  C07K14/4703 ,  A61K38/00 ,  C07K2319/30

Abstract: The disclosure provides compositions, methods, and kits for treatment of a condition, disease or disorder characterized by elevated trypsin activity or level, e.g., pancreatitis.

公开(公告)号：US20240182406A1

公开(公告)日：2024-06-06

申请号：US18552146

申请日：2022-03-14

Applicant: UNIVERSITAT DE BARCELONA

Inventor： Sandra CODONY I GISBERT ,  Cristian Gaspar GRIÑAN FERRE ,  Mercè PALLÀS LLIBERIA ,  Santiago VÁZQUEZ CRUZ ,  Yumin OH

IPC: C07C275/26 ,  A61K31/17 ,  A61K31/445 ,  A61K31/453 ,  A61P1/18 ,  A61P25/08 ,  A61P25/28 ,  C07D211/58 ,  C07D211/60 ,  C07D405/06

CPC classification number: C07C275/26 ,  A61K31/17 ,  A61K31/445 ,  A61K31/453 ,  A61P1/18 ,  A61P25/08 ,  A61P25/28 ,  C07D211/58 ,  C07D211/60 ,  C07D405/06

Abstract: The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I) to processes for their obtention and to their therapeutic indications.

公开(公告)号：US11959108B2

公开(公告)日：2024-04-16

申请号：US17460141

申请日：2021-08-27

Applicant: Codexis, Inc. ,  Societe des Produits Nestle S.A.

Inventor： Chinping Chng ,  Nikki Dellas ,  Ravi David Garcia ,  Moulay Hicham Alaoui Ismaili ,  Kristen Jean Vallieu ,  Kerryn McCluskie

IPC: C12N9/48 ,  A61K38/48 ,  A61P1/18

CPC classification number: C12N9/48 ,  A61K38/48 ,  A61P1/18

Abstract: The present invention provides engineered protease polypeptides and compositions thereof. The engineered protease polypeptides have been optimized to provide improved activity, improved thermostability, protease stability, autolytic stability, and stability under a range of pH conditions, including acidic (pH 7) conditions. The invention also relates to the use of the compositions comprising the engineered protease polypeptides for therapeutic and/or nutritional purposes. The present invention also provides polynucleotides encoding the engineered protease polypeptides, as well as methods for making the engineered polynucleotides and protease polypeptides.

公开(公告)号：US20230348617A1

公开(公告)日：2023-11-02

申请号：US17820440

申请日：2022-08-17

Applicant: City of Hope

Inventor： Saul J. Priceman ,  Christine E. Brown ,  Stephen J. Forman

IPC: C07K16/30 ,  A61P35/04 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C07K14/73 ,  C07K14/705 ,  C12N5/0783 ,  C07H21/00 ,  C07H21/04 ,  C12N15/63 ,  C12N15/11 ,  C12N15/00 ,  C12N15/10 ,  C12N5/00 ,  C12N15/09 ,  C12N15/79 ,  C12N15/70 ,  C12N15/62 ,  C12N15/85 ,  C12N15/74 ,  C12N5/078 ,  C12N5/071 ,  A61P19/08 ,  A61K48/00 ,  A61P1/18 ,  C12N5/07 ,  C12N5/10

CPC classification number: C07K16/3069 ,  A61P35/04 ,  A61P35/00 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C07K14/70521 ,  C12N5/0636 ,  C07H21/00 ,  C07H21/04 ,  C12N15/63 ,  C12N15/11 ,  C12N15/00 ,  C12N15/10 ,  C12N5/00 ,  C12N15/09 ,  C12N15/79 ,  C12N15/70 ,  C12N15/62 ,  C12N15/85 ,  C12N15/74 ,  C12N5/0634 ,  C12N5/0602 ,  A61P19/08 ,  A61K48/00 ,  A61P1/18 ,  C12N5/06 ,  C12N5/10 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C07H19/06

Abstract: Chimeric transmembrane immunoreceptors (CAR) targeted to PSCA are described.

公开(公告)号：US20230338387A1

公开(公告)日：2023-10-26

申请号：US17760181

申请日：2021-02-03

Applicant: NOF CORPORATION

Inventor： Yuichiro Uchida ,  Toshihiko Masui ,  Yasuhiko Tabata

IPC: A61K31/536 ,  A61K31/365 ,  A61K47/10 ,  A61K9/00 ,  A61P1/18

CPC classification number: A61K31/536 ,  A61K31/365 ,  A61K47/10 ,  A61K9/0024 ,  A61P1/18

Abstract: The present invention provides a prophylactic or therapeutic agent for the leakage of pancreatic juice and/or pancreatic fistula after abdominal surgery, containing a lipase inhibitor as an active ingredient, and a method for preventing or treating leakage of pancreatic juice and/or pancreatic fistula after abdominal surgery, including administering an effective amount of a lipase inhibitor to a mammal in need of the administration thereof.

公开(公告)号：US11767519B2

公开(公告)日：2023-09-26

申请号：US17460147

申请日：2021-08-27

Applicant: Codexis, Inc. ,  Societe des Produits Nestle S.A.

Inventor： Chinping Chng ,  Nikki Dellas ,  Da Duan ,  Ravi David Garcia ,  Harvinder Chagger Maniar

IPC: A61K38/47 ,  A61P1/18 ,  C12N9/26

CPC classification number: C12N9/2414 ,  A61K38/47 ,  A61P1/18 ,  C12Y302/01001

Abstract: The present invention provides engineered amylase polypeptides and compositions thereof. The engineered amylase polypeptides have been optimized to provide improved thermostability, protease stability, and stability under a range of pH conditions, including acidic (pH

公开(公告)号：US11744868B1

公开(公告)日：2023-09-05

申请号：US18107255

申请日：2023-02-08

Applicant: Jilin Agricultural University

Inventor： Qi Wang ,  Yu Yang ,  Yang Liu ,  Ling Su

IPC: A61K36/07 ,  A61K31/721 ,  A61P35/00 ,  A61P1/18

CPC classification number: A61K36/07 ,  A61K31/721 ,  A61P1/18 ,  A61P35/00 ,  A61K2236/331 ,  A61K2236/333 ,  A61K2236/53

Abstract: Disclosed are an Inonotus Obliquus dextran, a preparation method and application thereof, and relates to the field of medicines. The dextran has a structural formula as follows:




By optimizing the extraction and isolation process, the present disclosure obtains an Inonotus Obliquus dextran, which is structurally determined to be a new polysaccharide. The Inonotus Obliquus dextran prepared by the present disclosure is combined with gemcitabine hydrochloride to inhibit tumor cells with anti-tumor activity against pancreatic cancer, in addition to reduce the dosage of chemotherapeutic drugs as well as the adverse effects of chemotherapeutic drugs.

公开(公告)号：US20230220399A1

公开(公告)日：2023-07-13

申请号：US17923864

申请日：2021-05-07

Applicant: INTEROLIGO CORPORATION

Inventor： Jong Ook LEE ,  Jung Hwan LEE ,  Do Young KIM ,  Han Seul PARK ,  Se Na LEE ,  Da Gyeong LEE ,  So Yeon KIM ,  Ji Ah CHOI

IPC: C12N15/115 ,  A61K31/7088 ,  C12N15/10 ,  A61P35/00 ,  A61P1/18

CPC classification number: C12N15/115 ,  A61K31/7088 ,  C12N15/1048 ,  A61P35/00 ,  A61P1/18 ,  C12N2310/16

Abstract: One aspect according to the present disclosure relates to a novel nucleic acid ligand which is a new class of nucleic acid compound, the existence of which was considered impossible in the prior art. The novel nucleic acid ligand has specific binding affinity with respect to at least two different targets having three-dimensional structures, and the binding sites for the at least two targets are formed in or from a single nucleic acid ligand. The novel nucleic acid ligand according the present disclosure can simultaneously solve several problems of existing aptamers that the prior art could not solve. One aspect according to the present disclosure relates to a novel screening method for identifying the above-mentioned novel nucleic acid ligand. The novel screening method uses a step for sequentially contacting at least two different targets having three-dimensional structures to screen a novel nucleic acid ligand that was previously thought impossible.

公开(公告)号：US20230193209A1

公开(公告)日：2023-06-22

申请号：US18177702

申请日：2023-03-02

Applicant: CRISPR Therapeutics AG

Inventor： Alireza Rezania ,  Valentin Sluch

IPC: C12N5/071 ,  C12N15/90 ,  A61K35/545 ,  C07K14/475 ,  C12N9/22 ,  C12N5/074 ,  C07K14/525 ,  A61K35/39 ,  C07K14/74 ,  C07K14/705 ,  A61P1/18 ,  C12N5/0735 ,  C12N15/85 ,  A61K38/00

CPC classification number: C12N5/0676 ,  C12N15/907 ,  A61K35/545 ,  C07K14/475 ,  C12N9/22 ,  C12N5/0696 ,  C07K14/525 ,  A61K35/39 ,  C07K14/70539 ,  C07K14/70532 ,  A61P1/18 ,  C12N5/0606 ,  C12N15/85 ,  C07K2319/035 ,  A61K38/00 ,  C12N2506/02 ,  C12N2510/00 ,  C07K2319/02 ,  C12N2506/45 ,  C07K2319/09 ,  C12N2506/03

Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor and/or survival factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes a survival factor, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor and/or a different survival factor.